MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL

NCT06793189 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

145

Enrollment

OTHER

Sponsor class

Conditions

Marginal Zone Lymphoma(MZL)

Interventions

DRUG: Obinutuzumab and Orelabrutinib
DRUG: Obinutuzumab, Orelabrutinib and Lenalidomide
DRUG: Orelabrutinib
DRUG: Orelabrutinib

Sponsor

Ruijin Hospital